FDG-PET/CT: New horizons in anal cancer - 11/05/09
Department of Radiation Oncology – Campus Box 8224, Washington University School of Medicine, Mallinckrodt Institute of Radiology, 4921 Parkview Place, CAM Lower Level, Saint Louis MO 63110, Missouri, USA.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Summary |
Anal cancer is an uncommon tumor with an incidence of about one case per 100,000 in most countries. Its incidence seems to be increasing because of exposure to human immunodeficiency virus (HIV) and human papillomavirus (HPV). Traditional pretreatment evaluations include physical examination and CT imaging of the pelvis. Current treatment guidelines include fluorodeoxyglucose positron emission tomography integrated with computed tomography (FDG-PET/CT) as part of the standard pretreatment workup of patients diagnosed with anal cancer. At diagnosis, FDG-PET/CT is used to evaluate primary tumor size, lymph node status and to evaluate for distant metastases. FDG-PET/CT can also be used for radiation therapy treatment planning by clearly defining sites of metabolically active tumor. Posttherapy FDG-PET/CT to determine response to therapy is highly predictive of long-term clinical outcomes. This imaging modality can also be used to evaluate sites of recurrent disease. FDG-PET/CT is an imaging modality which greatly affects the management of patients with anal cancer.
Le texte complet de cet article est disponible en PDF.Plan
Vol 33 - N° 5
P. 456-458 - mai 2009 Retour au numéro
Article précédent
- La biopsie transrectale sous échographie endorectale des ganglions du mésorectum est-elle un examen de certitude lors du bilan d’extension locorégional des cancers du rectum ? Rapport d’un cas de faux-positif
- P.-E. Colombo, É. Assenat, M.-M. Bertrand, P. Senesse, F. Bibeau, P. Rouanet
Bienvenue sur EM-consulte, la référence des professionnels de santé.